Rani Therapeutics Holdings (RANI) Capital Expenditures (2020 - 2026)

Rani Therapeutics Holdings' Capital Expenditures history runs 7 years deep, the most recent figure standing at $15000.0 for Q1 2026.

• On a quarterly basis, Capital Expenditures fell 70.59% year-over-year to $15000.0 in Q1 2026; TTM through Mar 2026 was $52000.0, a 82.72% decrease from a year earlier, with the FY2025 full-year figure at $88000.0, down 67.16% from the prior year.
• Capital Expenditures fell to $15000.0 in Q1 2026 per RANI's latest filing, from $37000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $530000.0 in Q4 2022 and bottomed at -$333000.0 in Q3 2023.
• The 5-year median for Capital Expenditures is $85000.0 (2023), against an average of $133866.7.
• Across the five-year window, Capital Expenditures jumped 830.61% in 2022 and tumbled 173.03% in 2023, its largest moves.
• Year by year, Capital Expenditures stood at $530000.0 in 2022, then plunged by 143.77% to -$232000.0 in 2023, then jumped by 113.36% to $31000.0 in 2024, then grew by 19.35% to $37000.0 in 2025, then slumped by 59.46% to $15000.0 in 2026.
• Per Business Quant, the three latest RANI Capital Expenditures figures stand at $15000.0 (Q1 2026), $37000.0 (Q2 2025), and $51000.0 (Q1 2025).